- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.09. | Intensity Therapeutics auf der H.C. Wainwright Konferenz: Daten, Liquidität und entscheidende Meilensteine | - | Investing.com Deutsch | ||
| 11.08. | Intensity Therapeutics targets INVINCIBLE-4 enrollment completion by end of 2027 while seeking $30M to finish INVINCIBLE-3 | 1 | Seeking Alpha | ||
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.08. | Intensity Therapeutics GAAP EPS of -$1.11 misses by $0.14 | 1 | Seeking Alpha | ||
| 11.08. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.08. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | 577 | PR Newswire | Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026
... ► Artikel lesen | |
| 11.08. | INTENSITY THERAPEUTICS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 15.07. | Intensity Therapeutics resumes patient dosing in Swiss trial | 2 | Investing.com | ||
| 15.07. | Intensity Therapeutics setzt Patientendosierung in Schweizer Studie fort | - | Investing.com Deutsch | ||
| 15.07. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) | 191 | PR Newswire | First patients dosed in Switzerland
SHELTON, Conn., July 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a... ► Artikel lesen | |
| 08.07. | INTENSITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 01.07. | Intensity Therapeutics Inc.: Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 | 210 | PR Newswire | Late-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast cancer
Over 200 patients enrolled in completed INT230-6 studies... ► Artikel lesen | |
| 16.06. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Intensity Therapeutics GAAP EPS of -$0.96 | 1 | Seeking Alpha | ||
| 07.05. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | 642 | PR Newswire | Cash and cash equivalents of $10.2 million as of March 31, 2026
Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC")... ► Artikel lesen | |
| 01.05. | Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now | 1 | Zacks | ||
| 27.03. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update | 305 | PR Newswire | Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the second... ► Artikel lesen | |
| 12.03. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | 320 | PR Newswire | Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care... ► Artikel lesen | |
| 06.03. | Intensity Therapeutics Inc.: Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement | 319 | PR Newswire | SHELTON, Conn., March 6, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company... ► Artikel lesen | |
| 13.02. | Intensity Therapeutics Inc.: Intensity Therapeutics Announces Reverse Stock Split | 595 | PR Newswire | Intensity's common stock is expected to begin trading on a post-split adjusted basis on February 19, 2026
SHELTON, Conn., Feb. 13, 2026 /PRNewswire/ -- Intensity... ► Artikel lesen | |
| 13.01. | Intensity Therapeutics Inc.: Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities | 421 | PR Newswire | Peer-reviewed clinical validation, strengthened balance sheet, and disciplined execution position the Company for 2026
SHELTON, Conn., Jan. 13, 2026 /PRNewswire/... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,50 | 0,00 % | Nicht Bayer oder BioNTech: Diese attraktiv bewertete Biotechnologie-Aktie ist jetzt ein klarer Kauf! | © Foto: Sangharsh Lohakare auf Unsplash.Die Aktie von US-Biotechnologiekonzern Regeneron bietet nach einer Korrektur in den vergangenen Wochen eine fundamental attraktive Einstiegsgelegenheit.
Biotechnologie... ► Artikel lesen | |
| NOVAVAX | 11,300 | -0,70 % | Novavax-Aktie +20%: Woher kommt plötzlich die Fantasie? | Die Novavax-Aktie schoss zum Wochenauftakt um +20% in die Höhe und ging am Montagabend fast auf einem neuen 2-Jahreshoch aus dem Handel. Was steckt hinter dem Kurssprung des Impfstoffherstellers und... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,630 | -0,14 % | Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right. | ||
| INOVIO PHARMACEUTICALS | 1,024 | +0,10 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| INFLARX | 1,468 | +3,09 % | BRANDMELDUNG bei InflaRx NV: Meine brandneue Prognose ändert einfach alles - Handeln Sie noch vor dem Wochenende! | ||
| INTELLIA THERAPEUTICS | 11,800 | +1,03 % | Intellia Therapeutics-Aktie: Sind 80 US$ möglich? | Die Intellia-Therapeutics-Aktie notiert aktuell bei 12,37 US$ und damit mehr als -90% unter ihrem bisherigen Rekordhoch. Nach dem Ausbruch aus dem langjährigen Abwärtstrend versucht der Biotech-Titel... ► Artikel lesen | |
| EDITAS MEDICINE | 2,590 | 0,00 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,363 | -5,47 % | NurExone Biologic: Alle Zeichen stehen auf Ausbruch und Rallye! | ||
| IBIO | 0,839 | +6,95 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| GERON | 1,075 | 0,00 % | Geron-Aktie mit -98% - große Chance oder großes Risiko? | Die Geron-Aktie notiert aktuell bei 1,21 US$ und befindet sich erneut an einer langfristig wichtigen Unterstützungszone. Seit dem Zwischenhoch von 2024 hat der Biotech-Titel rund drei Viertel seines... ► Artikel lesen | |
| IMMUNITYBIO | 9,400 | +0,21 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 6,605 | 0,00 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 3,844 | 0,00 % | Myriad Genetics, Inc.: Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology | SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH)... ► Artikel lesen | |
| MANNKIND | 2,925 | -0,58 % | MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow' for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) | ||
| GINKGO BIOWORKS | 11,610 | -0,04 % | What's Going on With Ginkgo Bioworks Stock on Friday? |
INTENSITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 3,590 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.